Advertisement

Topics

Credit Suisse softens view on Teva, sees 21% downside risk; shares down 2% premarket

08:51 EDT 24 Aug 2017 | Topix

Bearish sentiment is still dogging Teva Pharmaceutical Industries . This morning, Credit Suisse downgraded the stock to Underperform and lowered its price target to $13 from $25.

Original Article: Credit Suisse softens view on Teva, sees 21% downside risk; shares down 2% premarket

NEXT ARTICLE

More From BioPortfolio on "Credit Suisse softens view on Teva, sees 21% downside risk; shares down 2% premarket"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...